Patents by Inventor Christopher Bayly

Christopher Bayly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused aromatic PTP-1B inhibitors
    Patent number: 9334295
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: May 10, 2016
    Assignee: KANEQ PHARMA INC.
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • FUSED AROMATIC PTP-1B INHIBITORS
    Publication number: 20150045325
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 12, 2015
    Applicant: Kaneq Pharma Inc.
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • Fused aromatic PTP-1B inhibitors
    Patent number: 8927526
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: January 6, 2015
    Assignee: Kaneq Pharma Inc.
    Inventors: John Colucci, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • FUSED AROMATIC PTP-1B INHIBITORS
    Publication number: 20130281365
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Application
    Filed: July 12, 2013
    Publication date: October 24, 2013
    Inventors: John COLUCCI, Marie-Claire WILSON, Yongxin HAN, Claude DUFRESNE, Michel BELLEY, Cheuk K. LAU, Christopher BAYLY
  • Fused aromatic PTP-1B inhibitors
    Patent number: 8481742
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: July 9, 2013
    Assignee: Kaneq Pharma Inc.
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • FUSED AROMATIC PTP-IB INHIBITORS
    Publication number: 20120178679
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Application
    Filed: March 13, 2012
    Publication date: July 12, 2012
    Applicant: KANEQ PHARMA INC.
    Inventors: John COLUCCI, Marie-Claire WILSON, Yongxin HAN, Claude DUFRESNE, Michel BELLEY, Cheuk K. LAU, Christopher BAYLY
  • Fused aromatic PTP-1B inhibitors
    Patent number: 8168815
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: May 1, 2012
    Assignee: Kaneq Pharma Inc.
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • CATHEPSIN CYSTEINE PROTEASE INHIBITORS
    Publication number: 20100063013
    Abstract: The present invention relates to novel compounds of the formula (I), wherein R?-R7, X, Y, D and n are as defined in the specification. These compounds are cysteine protease inhibitors which include but are not limited to inhibitors of cathepsms K, L, S and B and are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: March 25, 2008
    Publication date: March 11, 2010
    Inventors: Renata Oballa, Christopher Bayly, Jean-Francois Truchon, Chun Sing Li, Serge Leger
  • FUSED AROMATIC PTP-1B INHIBITORS
    Publication number: 20100022477
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Application
    Filed: January 24, 2008
    Publication date: January 28, 2010
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • Cathepsin Cysteine Protease Inhibitors
    Publication number: 20090253672
    Abstract: This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3, R4, R5, R6, R7, X and Y are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsms K L, S and B These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis
    Type: Application
    Filed: October 10, 2006
    Publication date: October 8, 2009
    Inventors: Serge Leger, Christopher Bayly, Jean-Francois Truchon
  • Cathepsin cysteine protease inhibitors
    Publication number: 20090176859
    Abstract: The present invention relates to a novel class of compounds mainly, leucinamide-amino-carboxylate derivatives of formula (I) wherein Y is CR1R2, O, S, —SO2, C=0 or NR9; Z is CR1R2, O, S, —SO2, C?O or NR9 and each G is independently a CR1CR2. Said compounds are cathepsin cysteine protease inhibitors, including but not limited to, inhibitors of cathepsin K, L, S and B and to pharmaceutical compositions thereof. These compounds are useful for treating and preventing cathepsin dependent conditions in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: January 6, 2005
    Publication date: July 9, 2009
    Inventors: Christopher Bayly, Cameron Black, Michel Therien
  • Cathepsin cysteine protease inhibitors
    Publication number: 20090176861
    Abstract: The present invention relates to a novel class of compounds mainly, substituted leucinamide-carboxylate derivatives of formula (I) wherein X is O or NR9, Y is CR1R2, —SO2, C?O or NR9; Z is CR1R2, O, S, —SO2 or NR9 and each G is independently a CR1CR2 and pharmaceutical compositions thereof. Said compounds are cathepsin cysteine protease inhibitors, including but not limited to, inhibitors of cathepsin K, L, S and B. These compounds are useful for treating and preventing cathepsin dependent conditions in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: January 6, 2005
    Publication date: July 9, 2009
    Inventors: Christopher Bayly, Sheldon N. Crane, Serge Leger
  • Methods for identifying modulators of P2RY14
    Publication number: 20090148850
    Abstract: Methods for identifying modulators of P2RY14 are described. The methods are particularly useful for identifying agents that are useful for treating metabolic syndrome.
    Type: Application
    Filed: October 1, 2008
    Publication date: June 11, 2009
    Inventors: Stacia Kargman, Martine Hamel, Joseph A. Mancini, Christopher Bayly
  • Cathepsin cysteine protease inhibitors
    Patent number: 7405229
    Abstract: This invention relates to a class of compounds having the general formula (I) which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Grant
    Filed: June 28, 2004
    Date of Patent: July 29, 2008
    Assignee: Merck Frosst Canada & Co.
    Inventors: Christopher Bayly, Cameron Black, Sheldon Crane, Daniel J. McKay, Renata Oballa, Joel Robichaud
  • Cathepsin cysteine protease inhibitors
    Publication number: 20070167635
    Abstract: This invention relates to a class of compounds having the general formula (I) which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: June 28, 2004
    Publication date: July 19, 2007
    Inventors: Christopher Bayly, Cameron Black, Sheldon Crane, Daniel McKay, Renata Oballa, Joel Robichaud
  • Cathepsin inhibitors
    Publication number: 20060287402
    Abstract: This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis.
    Type: Application
    Filed: August 23, 2004
    Publication date: December 21, 2006
    Inventors: Christopher Bayly, Cameron Black, Daniel McKay
  • Cathepsin cysteine protease inhibitors
    Publication number: 20050240023
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: February 28, 2003
    Publication date: October 27, 2005
    Inventors: Christopher Bayly, Cameron Black, Serge Leger, Chun Ku, Dan McKay, Christophe Mellon, Jacques Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien
  • Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
    Patent number: 6498151
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: December 24, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun Sing Li, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Cheuk Kun Lau, Patrick Roy, Michel Therien, Zhaoyin Wang, Claude Dufresne, Rejean Fortin
  • Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
    Patent number: 6486141
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related conditions.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Cheuk Kun Lau, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Chun Sing Li, Patrick Roy, Michel Therien, Zhaoyin Wang
  • Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
    Patent number: 6465444
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: October 15, 2002
    Assignees: Merck Frosst Canada & Co., Banyu Pharmaceutical Co., Ltd.
    Inventors: Christopher Bayly, Mitsuru Ohkubo